The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
12617894 |
6 |
An adjustable release rate linking strategy for cytotoxin-peptide conjugates. |
Tulane University Health Sciences Center |
26898814 |
154 |
SAR exploration at the C-3 position of tetrahydro-ß-carboline sstr3 antagonists. |
Merck Research Laboratories |
26199120 |
66 |
Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists. |
Merck Research Laboratories |
26005524 |
147 |
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes. |
Merck Research Laboratories |
25699156 |
24 |
Treating pain with somatostatin receptor subtype 4 agonists. |
Therachem Research Medilab (India) |
25050159 |
71 |
Investigation of Cardiovascular Effects of Tetrahydro-ß-carboline sstr3 antagonists. |
Merck Research Laboratories |
24944745 |
75 |
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists. |
Merck Research Laboratories |
18162395 |
89 |
Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst 1 receptor. |
Novartis Institutes For Biomedical Research |
17507221 |
58 |
Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists. |
Novartis Institutes For Biomedical Research |
24900499 |
67 |
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes. |
TBA |
24900466 |
55 |
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist. |
TBA |
24900340 |
40 |
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation. |
TBA |
20666484 |
40 |
Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. |
University of Firenze |
19351180 |
165 |
Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. |
The Clayton Foundation Laboratories For Peptide Biology |
19067538 |
110 |
Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities. |
Vrije Universiteit Brussel |
18543899 |
171 |
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. |
University of Berne |
18410084 |
115 |
Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity. |
Salk Institute |
18410083 |
30 |
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity. |
Salk Institute |
18210999 |
21 |
Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships. |
University of Firenze |
16220980 |
43 |
Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells. |
University of California San Diego |
15828816 |
100 |
N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. |
Technische Universit£T M£Nchen |
15658865 |
240 |
Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. |
Salk Institute |
15982879 |
61 |
3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists. |
Institut Henri Beaufour |
14667213 |
90 |
Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. |
Salk Institute |
14667212 |
110 |
Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. |
Salk Institute |
12477342 |
27 |
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery. |
Merck Research Laboratories |
11312929 |
90 |
Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. |
Tulane University Health Sciences Center |
11520208 |
45 |
Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. |
Institut Henri Beaufour |
9544214 |
197 |
Potent antagonists of somatostatin: synthesis and biology. |
Tulane University School of Medicine |
9632348 |
37 |
Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. |
Merck Research Laboratories |
11327607 |
67 |
Novel non-peptide ligands for the somatostatin sst3 receptor. |
Institut Henri Beaufour |
11266182 |
53 |
Synthesis of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5. |
Institut Henri Beaufour |
21806016 |
78 |
N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function. |
Salk Institute |
20684600 |
53 |
Biological diversity from a structurally diverse library: systematically scanning conformational space using a pyranose scaffold. |
Alchemia |
19786348 |
261 |
Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. |
F. Hoffmann-La Roche |
18020391 |
12 |
From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling. |
F. Hoffmann-La Roche |
18020390 |
37 |
Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. |
F. Hoffmann-La Roche |
17559206 |
22 |
New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold. |
Vrije Universiteit Brussel |
16854054 |
30 |
Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. |
Salk Institute |
16722631 |
87 |
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. |
Predix Pharmaceuticals |
15658864 |
225 |
Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. |
Salk Institute |
14667215 |
64 |
Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR. |
Salk Institute |
14667214 |
185 |
Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. |
Salk Institute |
11931620 |
40 |
Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. |
Hebrew University |
11405660 |
155 |
Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). |
Salk Institute |
11311064 |
84 |
N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity. |
Tulane University Health Sciences Center |
11212124 |
41 |
Nipecotic and iso-nipecotic amides as potent and selective somatostatin subtype-2 receptor agonists. |
Merck Research Laboratories |
11133079 |
10 |
Optimization of a somatostatin mimetic via constrained amino acid and backbone incorporation. |
University of California |
30735385 |
31 |
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo. |
Tarveda Therapeutics |
10354394 |
216 |
Highly potent cyclic disulfide antagonists of somatostatin. |
Tulane University School of Medicine |
10091708 |
32 |
Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. |
Merck Research Laboratories |
9667958 |
40 |
Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues. |
University of California San Diego |
9554871 |
43 |
Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis. |
University of Pennsylvania |
24378707 |
45 |
[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. |
Inrastes |
24342240 |
20 |
A tetradecapeptide somatostatin dicarba-analog: Synthesis, structural impact and biological activity. |
Institute For Research In Biomedicine (Irb Barcelona) |
17315859 |
12 |
Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. |
Diatide Research Laboaratories |
12773038 |
130 |
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. |
Novartis Pharma |
11448228 |
25 |
Peptide folding induces high and selective affinity of a linear and small beta-peptide to the human somatostatin receptor 4. |
Eth Zurich |
30429949 |
59 |
Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. |
Merck |
28988629 |
28 |
Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes. |
Takeda Pharmaceutical |
30015488 |
44 |
Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium. |
University of Florida |
26595185 |
30 |
Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies. |
Government College University |
25787859 |
13 |
Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. |
China Pharmaceutical University |
25283372 |
27 |
Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. |
Northeastern University |
19351113 |
30 |
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. |
Pfizer |
16275085 |
29 |
Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. |
Wyeth Research |
16759091 |
28 |
Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. |
National Tsing Hua University |